Questcor Pharmaceuticals (QCOR +13.07%) sits idle in the post session today as the company gets...

|By:, SA News Editor

Questcor Pharmaceuticals (QCOR +13.07%) sits idle in the post session today as the company gets its presentation at the BofA/Merrill health-care conference underway. While not likely to provide any sweeping new information, the presentation will paint a clearer picture of what lies ahead for Acthar gel in the realm of an alternative treatment for certain rheumatology-related conditions. According to Janney Montgomery spelling out the numbers of patients needing alternative treatment could what drove some shorts to cover today. Short interest on the stock stands at about 45%.